AbbVie (ABBV): analysis in plain words
Is AbbVie cheap or expensive? How it makes money, whether it grows and its risks, explained in plain words and with its official accounts.
AbbVie (ABBV) is listed on the NYSE and we classify it in healthcare and pharma. Below are its key dated figures, how it makes money, how it compares with its sector, what works for and against AbbVie according to those figures, and the questions people ask most about the stock. No buy or sell tips.
AbbVie (ABBV) key figures as of November 4, 2026
| Figure | Value | What it measures |
|---|---|---|
| Share price | $294.83 | Last price on November 4, 2026 |
| P/E ratio (TTM) | 50.7x | Price over earnings per share |
| Revenue growth | +10.3% | Latest quarter vs the same quarter a year earlier |
| Net margin (TTM) | 15.7% | Profit for every 100 of sales |
| Net debt / EBITDA | 2.0x | Years of operating profit to repay debt |
| Dividend yield | 2.42% | Annual dividend over price |
| Market cap | $521.0 billion | What the stock market values it at |
The AbbVie figures come from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026. Any ABBV figure that is not available shows as N/A: we do not estimate it.
How AbbVie makes money
AbbVie earns its money from branded drugs grouped into therapeutic areas: Immunology, led by Skyrizi, Rinvoq and Humira, is the biggest, followed by Oncology (Imbruvica, Venclexta), Neuroscience (Vraylar, therapeutic Botox) and Aesthetics (cosmetic Botox, Juvederm). The United States is by far its largest market.
Over the last 12 months, AbbVie brought in revenue of $66.0 billion. For every 100 it sells, AbbVie keeps 73.7 after the direct cost of what it sells (gross margin) and 39.5 after all operating costs (operating margin). With 57,000 full-time employees, that is about $1 million of revenue per employee.
AbbVie against its sector
To know whether a AbbVie figure is high or low you have to put it next to similar companies. This table compares AbbVie with the median of the 30 healthcare and pharma companies Fintols covers, with data as of November 4, 2026.
| Figure | AbbVie | healthcare and pharma median |
|---|---|---|
| P/E | 50.7x | 31.3x (30) |
| Revenue growth | +10.3% | +8.3% (33) |
| Net margin | 15.7% | 14.9% (33) |
| Dividend yield | 2.42% | 1.52% (33) |
| Net debt / EBITDA | 2.0x | 1.6x (31) |
In short, against the typical healthcare and pharma company, AbbVie trades on a higher P/E, grows faster and pays a higher dividend yield. By size, AbbVie ranks number 3 of 28 healthcare and pharma companies quoted in USD on Fintols.
The bull case for AbbVie
These are the strengths in the AbbVie figures as of November 4, 2026:
- Analysts expect AbbVie earnings to rise: its P/E on the next 12 months of estimated earnings is 18.2x, below the current 50.7x.
- AbbVie is selling more than a year ago: +10.3% in its latest quarter (the typical healthcare and pharma company grew +8.3%).
The main risk for AbbVie
The price already assumes a lot: AbbVie trades at 50.7x its last 12 months of earnings, against 31.3x for the healthcare and pharma median. If growth disappoints, the multiple can shrink and the share price with it.
And, like the rest of healthcare and pharma, AbbVie is exposed to a key drug losing patent protection or a clinical trial failing, plus government pressure on prices.
Frequently asked questions about AbbVie
Is it a good time to buy AbbVie stock?
Fintols does not tell you whether to buy or sell AbbVie, and nobody knows what the price will do tomorrow. What we can show you is where it stands today. As of November 4, 2026, AbbVie stock trades at $294.83, 1% below its 52-week high ($298.74) and 55% above its low ($190.75). Its P/E is 50.7x against a healthcare and pharma median of 31.3x, and 18.2x on the earnings analysts expect over the next 12 months. With AbbVie, as with any stock, timing matters less than understanding the business, investing for the long run and not betting everything on a single company.
Does AbbVie pay a dividend?
Yes. As of November 4, 2026, AbbVie pays $6.92 per share a year, which at today's price is a yield of 2.42%. It uses 117% of its profit to pay it, more than it earns, which cannot last forever. Its average dividend yield over the last five years is 3.41%. The healthcare and pharma median on Fintols is 1.52%.
Is AbbVie stock expensive?
It depends on what you compare it with. On P/E, AbbVie trades at 50.7x its last 12 months of earnings: more expensive than the healthcare and pharma median (31.3x). Including its debt, AbbVie is valued at 18.0x its EBITDA (EV/EBITDA). A high P/E alone does not make AbbVie expensive: it can be justified if earnings grow fast, and a low one can reflect a business in trouble.
Who are AbbVie's competitors?
On Fintols we compare AbbVie with Abbott, Amgen and Eli Lilly, which are also in healthcare and pharma. As of November 4, 2026, Abbott is worth $199.9 billion and trades on a P/E of 42.9; Amgen is worth $258.7 billion and trades on a P/E of 29.7; Eli Lilly is worth $1.26 trillion and trades on a P/E of 46.0. Each has a side-by-side comparison with AbbVie below.
AbbVie competitors
- Abbott (ABT) analysis · AbbVie vs Abbott comparison
- Amgen (AMGN) analysis · AbbVie vs Amgen comparison
- Eli Lilly (LLY) analysis · AbbVie vs Eli Lilly comparison
To understand AbbVie better
- DCF and WACC Explained: A Practical Valuation Guide
- P/E Ratio and EPS Explained: How to Read Them Without Traps
More companies like AbbVie: healthcare and pharma stocks, S&P 500 companies and S&P 100 companies. Open the full ABBV analysis with its valuation and scenarios. Educational content about AbbVie, not investment advice.